Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach

Breast Cancer. 2011 Jan;18(1):64-7. doi: 10.1007/s12282-010-0198-5. Epub 2010 Mar 31.

Abstract

A suggestive case of metastatic disease from breast cancer is reported. The HER-2-positive tumor was refractory to several agents, including anti-HER-2 therapy, trastuzumab, and lapatinib. After re-induction of trastuzumab in combination with activated natural killer (NK) cell injection therapy, tumor markers decreased, and finally a synergistic effect of taxane and capecitabine led to treatment response. This case suggests that multidisciplinary therapy including an immunological approach might be a breakthrough in the treatment of refractory disease.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Bridged-Ring Compounds / administration & dosage
  • Capecitabine
  • Carcinoma, Ductal, Breast / immunology
  • Carcinoma, Ductal, Breast / secondary
  • Carcinoma, Ductal, Breast / therapy*
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Drug Resistance, Neoplasm
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Killer Cells, Natural / transplantation*
  • Lapatinib
  • Lung Neoplasms / immunology
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy*
  • Middle Aged
  • Prognosis
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / metabolism
  • Salvage Therapy
  • Taxoids / administration & dosage
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bridged-Ring Compounds
  • Quinazolines
  • Taxoids
  • Lapatinib
  • Deoxycytidine
  • taxane
  • Capecitabine
  • Receptor, ErbB-2
  • Trastuzumab
  • Fluorouracil